"Mannkind Corporation (MNKD) has been hammered by bad news and a bad market, but some recent insider buying and the potential of Afrezza to eventually be an FDA-approved, inhaled insulin alternative to the needle for diabetics keeps this one as an intriguing pick to eventually realize a wallop of a rebound.

When the FDA last denied Mannkind an Afrezza approval, it was not the efficacy that concerned the regulatory agency, but the fact that the trial was conducted with a different inhaler than the one the company intended to market. That bodes well for the success of the next trials.

Investor concerns of financing continue to plague the share price, but with Al Mann already a billion dollars-plus invested in his company, these concerns may be unwarranted."

http://www.wallstreetwindow.com/aggregator/categories/1